export default function TriptorelinOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Triptorelin (Trelstar) is FDA-approved for prostate cancer and central precocious puberty. Its defining feature: continuous receptor stimulation causes testosterone and estrogen to collapse to near-zero levels within a few weeks. This is chemical castration by design — the intended therapeutic outcome for the indications it&rsquo;s approved for. Depot formulations lasting one to six months mean a single injection commits to weeks or months of hormonal suppression that cannot be reversed on demand.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; Clinical Context (Cancer, Endometriosis)</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;My doctor prescribed triptorelin for my prostate cancer. I understand it lowers testosterone, but I want to understand what that actually means for my body and for how long.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re considering it</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Testosterone suppression is the mechanism that controls hormone-sensitive cancers</strong><br />Many prostate cancers grow faster in the presence of testosterone. Eliminating testosterone through chemical means — which triptorelin does reliably within 2-4 weeks — deprives the cancer of its growth signal. For the right patient and cancer stage, this is well-established, effective oncological strategy backed by decades of clinical data.</li>
          <li><strong>Depot formulations mean consistent treatment without daily medication</strong><br />A single injection delivers controlled drug release over one, three, or six months. In a cancer treatment context where adherence matters and frequent medical visits are often already part of care, a depot that eliminates daily dosing is a genuine clinical convenience.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Testosterone suppression has systemic consequences that begin within weeks: bone density loss (significant after three to six months of suppression), muscle mass atrophy, cardiovascular risk changes, hot flashes, mood effects, and sexual dysfunction. In clinical oncology, these trade-offs are accepted because the alternative — uncontrolled cancer growth — is worse. Prostate cancer management routinely includes bone density monitoring, vitamin D and calcium supplementation, and consideration of bone-protecting drugs alongside triptorelin. Patients should discuss each of these proactively with their oncologist, not wait to be told. Net: for the approved indications, triptorelin is effective and appropriate — but the side effect profile requires active management, not passive monitoring.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; Hormone Management and TRT Context</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve seen triptorelin mentioned in TRT and post-cycle therapy forums. Some people say it can restart natural testosterone production. Is that accurate?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re curious</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The confusion with gonadorelin is understandable but dangerous</strong><br />Gonadorelin is a short-acting pulsatile signal that tells the pituitary to produce LH and FSH, which then signal the testes — it supports or restores testosterone production. Triptorelin looks superficially similar (both work at the same receptor) but does the opposite through continuous stimulation: it desensitizes the receptor and shuts down the entire chain. Understanding why they&rsquo;re opposite matters enormously here.</li>
          <li><strong>The interest in hormonal axis management after anabolic steroid use is legitimate</strong><br />People coming off anabolic steroid cycles have suppressed natural testosterone production and need the hypothalamic-pituitary-gonadal axis to recover. That&rsquo;s a real clinical problem, and the choice of compounds to support recovery (SERMs, gonadorelin, HCG) is a genuinely important decision. Triptorelin is not one of those compounds.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Using triptorelin as post-cycle therapy is a pharmacological error — not a fringe risk, an actual inversion of what the drug does. PCT requires axis stimulation to restart testosterone production. Triptorelin suppresses the axis further, extending the suppression period and deepening the hormonal crash. The only TRT-adjacent use that makes any sense for triptorelin is in gender-affirming hormone therapy under physician oversight, where suppression is the goal. Anyone who has seen triptorelin described as a PCT agent in forums is reading misinformation. Net: do not use this compound in any hormone optimization context without a physician who understands both the oncological pharmacology and the HPG axis consequences.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; HPG Axis Pharmacology and Hormonal Control</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;The pulsatile vs. continuous GnRH receptor distinction is one of the more elegant examples of how timing determines pharmacological direction. What does triptorelin actually reveal about HPG axis control?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Continuous vs. pulsatile stimulation as a mechanism is pharmacologically profound</strong><br />The same receptor — hit continuously — produces the opposite response from what pulsatile stimulation produces. This is one of the clearest examples in pharmacology of how administration timing, not just molecular target, determines pharmacological direction. Triptorelin is a useful case study in understanding why receptor desensitization matters for drug design.</li>
          <li><strong>Chemical castration as an oncological strategy has decades of rigorous clinical evidence</strong><br />The prostate cancer indication is supported by large randomized trials and decades of post-market data. For someone interested in how hormonal axes are manipulated pharmacologically at the clinical level, triptorelin&rsquo;s evidence base is the most rigorous in the GnRH agonist class.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">There is no biohacking application for triptorelin that doesn&rsquo;t involve physician-managed hormonal suppression for a medical purpose. The depot duration — one to six months of inescapable hormonal suppression from a single injection — makes any experimental self-administration categorically inadvisable. The axis recovery after depot exhaustion takes months, not days, and recovery is not guaranteed with repeated dosing or underlying HPG dysfunction. The entire pharmacological interest of this compound for the optimization community is theoretical and mechanistic — useful for understanding how the axis works, not as an intervention. Net: fascinating pharmacology, dangerous as a self-administered compound, appropriate only in physician-managed clinical contexts.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Triptorelin is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>A testosterone-stimulating compound — it suppresses the entire hormonal axis; continuous receptor stimulation causes the opposite of pulsatile stimulation</li>
              <li>Appropriate for post-cycle therapy — using it for PCT worsens suppression; SERMs and gonadorelin are the axis-stimulating options</li>
              <li>Reversible on demand — depot formulations last one to six months; there is no &ldquo;stop and wait a day&rdquo; option</li>
              <li>Similar to gonadorelin — same receptor, diametrically opposite pharmacological effect due to continuous vs. pulsatile dosing</li>
              <li>Safe for unmonitored self-administration — bone density, cardiovascular, and recovery risks require physician monitoring</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>One of the clearest pharmacological examples of timing determining direction — same receptor, opposite effect based on continuous vs. pulsatile administration</li>
              <li>Decades of rigorous oncological clinical data in prostate cancer — a well-characterized compound in its approved indications</li>
              <li>FDA-approved (Trelstar) for prostate cancer and precocious puberty; EU-approved for endometriosis and uterine fibroids</li>
              <li>Used in gender-affirming hormone therapy as puberty blockers under physician oversight</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
